FDA Approves New Alzheimer’s Treatment That May Slow Decline in Memory

By Jack Phillips The U.S. Food and Drug Administration (FDA) on Tuesday approved a new Alzheimer’s treatment called donanemab, which could slow progression of the mental disease that impacts millions of Americans, drugmaker Eli Lilly said. The drug, which will be sold under the name Kisunla, is a type of monoclonal antibody infusion that is […]